A Phase 3 Multicenter Open-label Maintenance Study to Investigate the Long-term Safety of ZS (Sodium Zirconium Cyclosilicate) in Japanese Subjects With Hyperkalemia
Phase of Trial: Phase III
Latest Information Update: 07 Oct 2017
At a glance
- Drugs Zirconium silicate (Primary)
- Indications Hyperkalaemia
- Focus Adverse reactions
- Sponsors AstraZeneca
- 06 Sep 2017 Planned End Date changed from 5 Aug 2019 to 10 Sep 2019.
- 06 Sep 2017 Planned primary completion date changed from 5 Aug 2019 to 10 Sep 2019.
- 27 Jun 2017 Status changed from not yet recruiting to recruiting.